From the Editor
To better engage our readership on the economic, policy, and practice issues affecting the oncology community, we have updated our editorial and changed our name, bringing more value-added content to the pages of Cancer Care Practice & Policy (CCP&P).
To better engage our readership on the economic, policy, and practice issues affecting the oncology community, we have updated our editorial and changed our name, bringing more value-added content to the pages of Cancer Care Practice & Policy (CCP&P). In the upcoming issues, our editors will develop regular columns on topics ranging from billing & coding problems to legal advice and practice management tips, all of which are designed to give quick-reading, issue-solving information for today’s busy oncologists.
Along with the regular feature departments, we will also report on the broader political actions and initiatives that influence the practice of oncology. To that end, we will continue to build our working relationship with ASCO, ASH, and ACCC to deliver consensus-driven views from leading experts on issues such as the impending work-force shortage of medical and gynecological oncologists, the challenges of implementing HIT, cancer care quality initiatives, and regulatory and advocacy issues.
As always, we encourage our readers to share their thoughts, advice, or opinions about anything that appears on these pages. [Please send comments to: Ronald.Piana@cmpmedica.com.]
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
